Skribe Medical develops wearable cardiac monitoring for cancer care. The U.S. startup raised US$1.65 million in Pre-Seed funding. SeaX Ventures led the round, with GoAhead Ventures and Marin Sonoma Impact Ventures also participating.
FDA selection and study enrollment
The Aurora System was selected for the FDA READI-Home Innovation Challenge. More than 800 patients have enrolled in the NOECHO study. The study compares Skribe's wearable measurements with echocardiography.
Company and founders
Skribe was founded by Ryan Neely, Josh Kay, and Andrew Bohannon. The three previously worked at iota Biosciences, which Astellas Pharma acquired. Skribe is also developing a platform called Resonant Body Power and Communication.
What Aurora does
Aurora combines a multi-sensor adhesive patch with AI analysis. It estimates left ventricular ejection fraction. The system is designed for use during oncology visits, with home monitoring as a longer-term goal.
SeaX Ventures helped arrange hospital collaborations in Southeast Asia. The firm supported recruitment of more than 100 patients for Skribe's clinical studies. Skribe is advancing its technology toward broader clinical adoption.